EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

The complete response letter did not identify any issues with the safety or efficacy of Eylea HD, Regeneron officials said.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...

such as retinopathy of prematurity (ROP), to their later years, including diabetic macular edema (DME), diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO) and wet age ...

Discover surprising truths about blindness, from the spectrum of visual impairment to revolutionary treatments and adaptive ...

An increasing incidence of retinopathy of prematurity as seen in Latin America. An increasing urbanization. A lack of proper health policy. A lack of uniform accessible comprehensive and adequate ...

and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and ...

The second, was Premacure AB, allowing Shire's HGT business to continue the ongoing development a protein replacement therapy for the treatment of retinopathy of prematurity (ROP). The third and ...